Anti-Neutrophil Bactericidal Protein BP30 antibody (ab101862)
- Product nameAnti-Neutrophil Bactericidal Protein BP30 antibody
- DescriptionRabbit polyclonal to Neutrophil Bactericidal Protein BP30
- Tested applicationsWB, IHC-P, IHC-Fr more details
- Species reactivityReacts with: Human
A synthetic peptide from the N terminal region of Human Neutrophil Bactericidal Protein BP30 conjugated to an immunogenic carrier protein.
- Storage instructionsStore at +4°C short term (1-2 weeks). Add glycerol to a final volume of 50%, aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: None
Constituents: Whole serum
- PurityWhole antiserum
- Clonality Polyclonal
- Research Areas
Our Abpromise guarantee covers the use of ab101862 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: 1/100 - 1/2000. Predicted molecular weight: 54 kDa. This antibody has been tested in Western blot against the recombinant peptide used as an immunogen. We have no data on detection of endogenous protein.|
|IHC-P||IHC-P: 1/100 - 1/2000. Antigen retrieval is recommended before commencing with IHC staining protocol.|
|IHC-Fr||IHC-Fr: 1/100 - 1/2000.|
- FunctionThe cytotoxic action of BPI is limited to many species of Gram-negative bacteria; this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to the Gram-negative bacterial outer envelope. Has antibacterial activity against the Gram-nagative bacterium P.aeruginosa, this activity is inhibited by LPS from P.aeruginosa.
- Tissue specificityRestricted to cells of the myeloid series.
- Sequence similaritiesBelongs to the BPI/LBP/Plunc superfamily. BPI/LBP family.
- DomainThe N-terminal region may be exposed to the interior of the granule, whereas the C-terminal portion may be embedded in the membrane. During phagocytosis and degranulation, proteases may be released and activated and cleave BPI at the junction of the N-and C-terminal portions of the molecule, providing controlled release of the N-terminal antibacterial fragment when bacteria are ingested.
- Cellular localizationSecreted. Cytoplasmic granule membrane. Membrane-associated in polymorphonuclear Leukocytes (PMN) granules.
- Bactericidal permeability-increasing protein antibodyBactericidal/permeability increasing protein antibodyBPI antibody
- BPI_HUMAN antibodyCAP 57 antibodyCAP57 antibody
References for Anti-Neutrophil Bactericidal Protein BP30 antibody (ab101862)
ab101862 has not yet been referenced specifically in any publications.